Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.

Détails

ID Serval
serval:BIB_9D8D1725E989
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Périodique
Gastroenterology
Auteur(s)
Dao Thi V.L., Debing Y., Wu X., Rice C.M., Neyts J., Moradpour D., Gouttenoire J.
ISSN
1528-0012 (Electronic)
ISSN-L
0016-5085
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
150
Numéro
1
Pages
82-85.e4
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.
Mots-clé
Antiviral Agents/administration & dosage, Antiviral Agents/pharmacology, Chronic Disease, Drug Synergism, Drug Therapy, Combination, Hepatitis E/drug therapy, Hepatitis E virus/drug effects, Hepatitis E virus/physiology, Humans, In Vitro Techniques, RNA, Viral/drug effects, RNA, Viral/physiology, Ribavirin/administration & dosage, Ribavirin/pharmacology, Sofosbuvir/administration & dosage, Sofosbuvir/pharmacology, Virus Replication/drug effects
Pubmed
Web of science
Création de la notice
11/01/2016 18:18
Dernière modification de la notice
20/08/2019 16:03
Données d'usage